Amicus Therapeutics EBITDA vs. Operating Margin

FOLD Stock  USD 10.15  0.01  0.1%   
Based on Amicus Therapeutics' profitability indicators, Amicus Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Amicus Therapeutics' ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-92.1 M
Current Value
-96.7 M
Quarterly Volatility
99.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of December 13, 2024, Price To Sales Ratio is expected to decline to 9.96. In addition to that, Days Sales Outstanding is expected to decline to 76.09. At present, Amicus Therapeutics' Income Tax Expense is projected to increase significantly based on the last few years of reporting. The current year's Non Operating Income Net Other is expected to grow to about 6.8 M, whereas Income Before Tax is forecasted to decline to (157.6 M).
For Amicus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Amicus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Amicus Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Amicus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Amicus Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Revenue Per Share
1.629
Quarterly Revenue Growth
0.367
Return On Assets
0.0116
Return On Equity
(0.67)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Amicus Therapeutics Operating Margin vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Amicus Therapeutics's current stock value. Our valuation model uses many indicators to compare Amicus Therapeutics value to that of its competitors to determine the firm's financial worth.
Amicus Therapeutics is rated below average in ebitda category among its peers. It is rated # 3 in operating margin category among its peers . At present, Amicus Therapeutics' EBITDA is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Amicus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Amicus Operating Margin vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Amicus Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(92.08 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Amicus Therapeutics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.18 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Amicus Operating Margin Comparison

Amicus Therapeutics is currently under evaluation in operating margin category among its peers.

Amicus Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Amicus Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Amicus Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Amicus Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Amicus Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income5.2 M5.5 M
Operating Income-73.5 M-77.2 M
Income Before Tax-150.1 M-157.6 M
Total Other Income Expense Net-76.6 M-72.8 M
Net Loss-151.6 M-159.2 M
Income Tax Expense1.5 M1.6 M
Net Loss-173.6 M-182.3 M
Non Operating Income Net Other6.5 M6.8 M
Net Loss-212.9 M-223.6 M
Interest Income7.4 MM
Net Interest Income-41 M-39 M
Change To Netincome89.2 M61.4 M
Net Loss(0.51)(0.54)
Income Quality 0.46  0.43 
Net Income Per E B T 1.01  0.77 

Amicus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Amicus Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Amicus Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Amicus Therapeutics' important profitability drivers and their relationship over time.

Use Amicus Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amicus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amicus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Amicus Therapeutics Pair Trading

Amicus Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Amicus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amicus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amicus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amicus Therapeutics to buy it.
The correlation of Amicus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amicus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amicus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amicus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Amicus Therapeutics position

In addition to having Amicus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Market ETFs Thematic Idea Now

Broad Market ETFs
Broad Market ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 62 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Investing Opportunities.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
To fully project Amicus Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Amicus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Amicus Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Amicus Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Amicus Therapeutics investors may work on each financial statement separately, they are all related. The changes in Amicus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Amicus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.